Renflexis is a Intravenous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Organon Llc. The primary component is Infliximab.
| Product ID | 78206-162_488396cb-243a-45bf-b936-fcde5dcdb465 | 
| NDC | 78206-162 | 
| Product Type | Human Prescription Drug | 
| Proprietary Name | Renflexis | 
| Generic Name | Infliximab | 
| Dosage Form | Injection, Powder, Lyophilized, For Solution | 
| Route of Administration | INTRAVENOUS | 
| Marketing Start Date | 2017-04-21 | 
| Marketing Category | BLA / | 
| Application Number | BLA761054 | 
| Labeler Name | Organon LLC | 
| Substance Name | INFLIXIMAB | 
| Active Ingredient Strength | 100 mg/1 | 
| Pharm Classes | Tumor Necrosis Factor Blocker [EPC],Tumor Necrosis Factor Receptor Blocking Activity [MoA] | 
| NDC Exclude Flag | N | 
| Listing Certified Through | 2022-12-31 | 
| Marketing Start Date | 2021-06-01 | 
| NDC Exclude Flag | N | 
| Sample Package? | N | 
| NDC | Brand Name | Generic Name | 
|---|---|---|
| 0006-4305 | Renflexis | infliximab | 
| 78206-162 | Renflexis | infliximab | 
| 57894-160 | INFLIXIMAB | INFLIXIMAB | 
| 57894-030 | REMICADE | INFLIXIMAB | 
| Mark Image Registration | Serial | Company Trademark Application Date | 
|---|---|
|  RENFLEXIS  87480588  5542207 Live/Registered | Merck Sharp & Dohme Corp. 2017-06-08 | 
|  RENFLEXIS  86307793  5311653 Live/Registered | Merck Sharp & Dohme Corp. 2014-06-12 |